Skip to main content
. 2020 Apr 10;47(6):569–577. doi: 10.1111/1346-8138.15343

Table 3.

Summary of treatment‐related adverse events (≥3% of patients; safety analysis population)

PT Treatment‐related adverse events in patients (n = 129)
n (%)
All 83 64.3
Nasopharyngitis 29 22.5
Influenza 9 7.0
Folliculitis 8 6.2
Oral candidiasis 9 7.0
Cellulitis 5 3.9
Pharyngitis 5 3.9
Arthralgia 5 3.9
Skin papilloma 5 3.9
Periodontitis 4 3.1
Diarrhea 4 3.1
Upper respiratory tract inflammation 4 3.1
Pyrexia 4 3.1

PT, preferred term.